Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

FHS
July 5, 2023
4:22 pm

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

Bluebird’s $175M loan; Spyre reveals second private placement

Plus, news about Fennec, AstraZeneca, BiomX and Pfizer: Bluebird bio gets more money: The gene therapy maker inked a five-year, $175 million loan facility with

March 19, 2024

Study shows RSV’s severe impact on US adults, urging more testing and vaccination

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the need for awareness and prevention efforts.

November 14, 2024

Reinforcement feedback improves motor learning: The role of striatal oscillatory activity explored

The causal contribution of specific oscillatory activity patterns within the human striatum to reinforcement motor learning using transcranial temporal interference stimulation.

May 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.